Sector News

Protagen AG Appoints Bernhard Kirschbaum as New Board Member

January 9, 2015
Life sciences
(BUSINESS WIRE) – PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.
 
This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.
 
Dr. Kirschbaum has served in executive positions at Hoechst, Aventis, Sanofi, and Merck Serono, and has a proven track record in preclinical and clinical R&D, with a special focus on autoimmune diseases and chronic inflammatory disorders. According to Dr. Kirschbaum, “Protagen offers a very solid, unique technology with broad application potential. It is of particular relevance for translational research, which remains a central topic in drug development. In many diseases, analyses at the protein level offer key insights and guidance on diseases status and drug development.”
 
Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of CDx for autoimmune therapy, it is imperative that we have meaningful insight into the R&D processes and interfaces of big pharma. The profound expertise Dr. Kirschbaum will bring to this role will provide us with valuable guidance, which will enable us to effectively expand our business within the growing CDx field.”
 
Source: Protagen 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach